

Siemens Healthcare Diagnostics GmbH, HC CEMEA CEE QT, Siemensstrasse 90, 1210 Vienna

Name Department

Telephone

Mobile F-mail

Date

M.A. Roland Ertl HC CEMEA CEE QT

+43 51707-38274 +43 (664) 8011738274 roland.re.ertl@siemens.com

August 1st, 2018

Document Ref# POC 18-010.A.OUS

Urgent Field Safety Notice:

RAPIDPoint® 405/500 Systems / RAPIDLab® 1245/1265 Systems

Hydroxocobalamin Interference

Dear Sirs,

Our records indicate that your facility may have received the following product:

System	Siemens Material Number (SMN)	
RAPIDPoint 405 Blood Gas Analyzer	10282093, 10310464, 10314817, 10317193, 10318999, 10320055, 10321238, 10322347, 10328278, 10328302, 10336784	
RAPIDPoint 500 Blood Gas Analyzer	10492730, 10696855, 10696857, 10697306	
RAPIDLab 1245 Blood Gas Analyzer	10321844, 10337179, 10491393	
RAPIDLab 1265 Blood Gas Analyzer	10321852, 10470366, 10491395	

Table 1. Affected Products

Note: All analyzer serial numbers are affected

Reason for this Urgent Field Safety Notice

Please be advised that Siemens Healthcare Diagnostics has determined that therapeutic levels (1 mg/mL and 2 mg/mL) of Hydroxocobalamin may interfere with tHb and some of the CO-Ox fractions that are reported on the RAPIDPoint and RAPIDLab Blood Gas Systems indicated in Table 1. Tables 2 and 3 below summarize the effect on tHb and CO-Ox fractions on samples that contain 1 mg/mL and 2 mg/mL of Hydroxocobalamin.

Siemens Healthcare Diagnostics GmbH Management: Wolfgang Koeppl, Stefan Scheidler Siemensstrasse 90 1210 Vienna Austria

Tel.: +43 51707 0 healthcare.siemens.com

Rechtsform: Gesellschaft mit beschraenkter Haftung; Firmensitz: Wien; Firmenbuchnummer: FN 135042 t; Firmenbuchgericht: Handelsgericht Wien; DVR: 0816540



Risk to Health

The risk to health is limited to Hydroxocobalamin interference causing lower than expected values for carboxyhemoglobin (fCOHb) and methemoglobin (fMetHb). A negative interference with fCOHb has the potential to alter the medical assessment of the patient and may withhold necessary follow-up treatment in response to elevated fCOHb levels. A negative interference with fMetHb has the potential to alter the medical assessment of the patient and may withhold necessary follow-up treatment of the patient and may withhold necessary follow-up treatment of the patient and may withhold necessary follow-up treatment and/or initiate cessation of medication in response to elevated fMetHb levels.

Total hemoglobin (tHb) is the total of all measured hemoglobin fractions, deoxyhemoglobin (fHHb) is the form of hemoglobin without oxygen and oxyhemoglobin (fO2Hb) is the fraction of hemoglobin that reversibly binds oxygen. These analytes are either not used in isolation or are not the testing reason for hemoglobin fractionation assessment in burn patients after a cyanide antidote has been given.

Siemens is not recommending a review of previously generated results.

Analyte	Expected Result	Recovery observed with a single dose of Hydroxocobalamin (1 mg/mL)	Recovery observed with a second dose of Hydroxocobalamin (2 mg/mL)
fCOHb	2%	N/A*	N/A*
fCOHb	20%	15.24%	10.48%
fMetHb	5%	3.01%	1.02%
fMetHb	20%	16.68%	13.36%
tHb	12 g/dL	11.41 g/dL	10.82 g/dL
tHb	18 g/dL	17.36 g/dL	16.72 g/dL
fO2Hb	80%	83.99%	87.98%
fO2Hb	95%	97.92%	NA*
fHHb	0.95%	0.27%	NA*

Table 2. Recovery observed on RAPIDPoint 405/500 Systems

Table 3. Recovery observed on RAPIDLab 1200 Systems

Analyte	Expected Result	Recovery observed with a single dose of Hydroxocobalamin (1 mg/mL)	Recovery observed with a second dose of Hydroxocobalamin (2 mg/mL)
fCOHb	2%	N/A*	N/A*
fCOHb	20%	14.74%	9.47%
fMetHb	5%	3.32%	1.64%
fMetHb	20%	16.27%	12.54%
tHb	12 g/dL	11.34 g/dL	10.68 g/dL
tHb	18 g/dL	17.72 g/dL	17.44 g/dL
fO2Hb	80%	84.56%	89.12%
fO2Hb	95%	97.37%	99.74%
fHHb	0.75%	0.25%	N/A*

*The data suggests this measurement would be outside the detection limit.

Note: Percentages are reported as absolute percentages.



Actions to be Taken by the Customer

- Please review this letter with your Medical Director.
- Complete and return the Field Correction Effectiveness Check Form attached to this letter within 7 days.

Please retain this letter with your laboratory records, and forward this letter to those who may have received this product.

Siemens will be revising the RAPIDPoint 500 and RAPIDLab 1200 Operators Guides with information on this interfering substance.

We apologize for the inconvenience this situation may cause. If you have any questions, please contact your Siemens Customer Care Center or your local Siemens technical support representative.

Sincerely yours,

Siemens Healthcare Diagnostics GmbH

i.V. Dipl. Ing. Franz Schwarz Head of RAQS Austria & SEE

i.A. Mag- Thomas Hufnagl Product Manager Austria & SEE